Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test
EyePoint Pharmaceuticals’ wet age-related macular degeneration (AMD) therapy has demonstrated non-inferiority to Regeneron’s Eylea, even with a less frequent dosing regimen in a mid-stage study, prompting its share price to rocket by more than 200% on Monday morning.
The biotech’s share price $EYPT now sits at around $20, up from $6.61 at previous close. Patients with wet AMD in the 56-week Phase II DAVIO 2 trial received a single injection of either 2 mg or 3 mg of EYP-1901, or bi-monthly injections of Eylea. The trial enrolled a total of 160 subjects who were previously dosed with at least two standard of care anti-VEGF injections in six months prior to screening.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.